270 related articles for article (PubMed ID: 29065104)
1. Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review.
Prawira A; Oosting SF; Chen TW; Delos Santos KA; Saluja R; Wang L; Siu LL; Chan KKW; Hansen AR
Br J Cancer; 2017 Dec; 117(12):1743-1752. PubMed ID: 29065104
[TBL] [Abstract][Full Text] [Related]
2. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
[TBL] [Abstract][Full Text] [Related]
3. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis.
Luo J; Xiao W; Hua F; Cao Y; Wang D; Wang X
BMC Cancer; 2023 Nov; 23(1):1172. PubMed ID: 38037076
[TBL] [Abstract][Full Text] [Related]
5. Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.
Lee VHF; Kwong DLW; Lam KO; Lai YC; Li Y; Tong CC; Ho PPY; Chan WL; Wong LS; Leung DKC; Chan SY; Chan FT; Leung TW; Lee AWM
Medicine (Baltimore); 2017 Apr; 96(15):e6518. PubMed ID: 28403082
[TBL] [Abstract][Full Text] [Related]
6. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial.
Peng H; Chen L; Li WF; Guo R; Mao YP; Zhang Y; Guo Y; Sun Y; Ma J
Cancer; 2017 May; 123(9):1643-1652. PubMed ID: 28001301
[TBL] [Abstract][Full Text] [Related]
7. Platinum-based concurrent chemotherapy remains the optimal regimen for nasopharyngeal carcinoma: a large institutional-based cohort study from an endemic area.
Yu Y; Liang H; Lv X; Ke L; Qiu W; Huang X; Liu G; Li W; Guo X; Xiang Y; Xia W
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2231-2243. PubMed ID: 30109501
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of early radiological response to first-line platinum-containing chemotherapy in patients with metastatic nasopharyngeal carcinoma.
Liu GY; Li WZ; Peng KQ; Lv X; Ke LR; Wu YS; Wang DL; Liang H; Liu KY; Lv SH; Guo X; Xiang YQ; Xia WX
Cancer Med; 2020 Feb; 9(3):920-930. PubMed ID: 31834990
[TBL] [Abstract][Full Text] [Related]
9. Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma.
Lin JC; Jan JS; Chen KY; Hsu CY; Liang WM; Wang WY
Head Neck; 2003 Jun; 25(6):438-50. PubMed ID: 12784235
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis.
Yeo BSY; Song HJJMD; Soong YL; Chua MLK; Ang MK; Lim DWT; See A; Lim CM
Oral Oncol; 2023 Jan; 136():106242. PubMed ID: 36413976
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy.
Hua YJ; Han F; Lu LX; Mai HQ; Guo X; Hong MH; Lu TX; Zhao C
Eur J Cancer; 2012 Dec; 48(18):3422-8. PubMed ID: 22835782
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
Peng PJ; Ou XQ; Chen ZB; Liao H; Peng YL; Wang SY; Zhang HY; Lin Z
Cancer Chemother Pharmacol; 2013 Aug; 72(2):323-8. PubMed ID: 23728706
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
15. Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma - How far have we achieved?
Lee V; Kwong D; Leung TW; Lam KO; Tong CC; Lee A
Crit Rev Oncol Hematol; 2017 Jun; 114():13-23. PubMed ID: 28477740
[TBL] [Abstract][Full Text] [Related]
16. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
17. Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study.
Lu Y; Huang H; Yang H; Hu X; Liu M; Huang C; Feng X; Chen X; Jiang Z
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4327-4338. PubMed ID: 36075994
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
[TBL] [Abstract][Full Text] [Related]
19. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms.
Ma BB; Hui EP; Wong SC; Tung SY; Yuen KK; King A; Chan SL; Leung SF; Kam MK; Yu BK; Zee B; Chan AT
Ann Oncol; 2009 Nov; 20(11):1854-9. PubMed ID: 19549713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
